| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointment of Thierry Chauche as Chief Financial Officer, effective today, May 6, 2024.
"We are thrilled to welcome Thierry to our executive leadership team in the role of CFO. Thierry brings a proven track record in corporate finance in the biopharmaceutical sector, bringing expertise in corporate planning and strategy, investor relations, financing, and M&A," said Dave Happel, CEO of Sagimet. "Having an experienced leadership team with the appropriate skillsets is critical at this key stage as we advance denifanstat into a registrational Phase 3 study following successful completion of a Phase 2b study where denifanstat demonstrated clinical results significantly reducing fat, inflammation and fibrosis."
"I am excited to join Sagimet as the company focuses on moving denifanstat into Phase 3 development," Mr. Chauche commented. "I am honored to have the opportunity to join the Sagimet team at this exciting time and to leverage my prior experience in helping the Company achieve its vision of bringing denifanstat to patients and driving shareholder value. I am looking forward to working with Dave and the Sagimet team, the board of directors, and our stakeholders."
Mr. Chauche brings to Sagimet more than twenty years of financial, strategic planning, and corporate leadership experience in finance and biopharma companies. Most recently he served as Chief Financial Officer of Provention Bio, a publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including Type 1 Diabetes, where he built up and led finance, investor relations, and information technology teams supporting market creation and a transformational therapeutic launch and commercialization. At Provention, he also focused on the successful execution of several financings, and an M&A strategy leading to a $2.9Bn acquisition of the company by Sanofi. Before Provention Bio, Mr. Chauche was the Vice President and Head of Strategic Financial Planning & Analysis at Alexion Pharmaceuticals. Prior to Alexion Pharmaceuticals, he served in roles of increasing responsibility at Intercept Pharmaceuticals, Novartis, and Rothschild & Cie. Mr. Chauche holds an MBA from the Wharton School at the University of Pennsylvania, and a MS in engineering from Ecole des Ponts ParisTech in Paris, France.
Posted In: SGMT
